Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...

PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...

The recommendation to add COPIKTRA ( duvelisib) to the NCCN Guidelines is based on the broad body of evidence and uniform consensus ( > 85% support of the NCCN Panel) that intervention is appropriate.

New guidelines provide a framework for pediatric neuroblastoma treatment — as well as conversations families should have with their oncology teams. Newly crafted guidelines could help guide the ...

The new interactive guideline tool represents a major format change for gold-standard NCCN Guidelines. "This is truly the future of cancer treatment guidance," said Crystal S. Denlinger, MD, Chief ...

Invivyd, Inc. has announced that its investigational monoclonal antibody, PEMGARDA® (pemivibart), has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for ...

The National Comprehensive Cancer Network (NCCN)—an alliance of leading cancer centers that publishes free evidence-based, expert consensus-driven guidelines for cancer prevention and care— announces ...

The National Comprehensive Cancer Network ® (NCCN ®) - an alliance of leading cancer centers - and the NCCN Foundation ® proudly announce plans to make every book in the library of NCCN Guidelines for ...

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to include duvelisib (Copiktra) as a category 2A treatment option for cutaneous T-cell ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...